Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$0.69.

  • X4 Pharmaceuticals' EPS (Basic) rose 8740.88% to -$0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.66, marking a year-over-year decrease of 196400.0%. This contributed to the annual value of -$0.19 for FY2024, which is 6727.9% up from last year.
  • Per X4 Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.69 for Q3 2025, which was up 8740.88% from -$3.47 recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' EPS (Basic) peaked at $13.59 during Q2 2024, and registered a low of -$7.77 during Q1 2024.
  • For the 5-year period, X4 Pharmaceuticals' EPS (Basic) averaged around -$0.55, with its median value being -$0.6 (2022).
  • Examining YoY changes over the last 5 years, X4 Pharmaceuticals' EPS (Basic) showed a top increase of 421818.18% in 2024 and a maximum decrease of 5470000.0% in 2024.
  • X4 Pharmaceuticals' EPS (Basic) (Quarter) stood at -$1.28 in 2021, then skyrocketed by 84.38% to -$0.2 in 2022, then soared by 55.0% to -$0.09 in 2023, then plummeted by 120.06% to -$0.2 in 2024, then tumbled by 248.39% to -$0.69 in 2025.
  • Its last three reported values are -$0.69 in Q3 2025, -$3.47 for Q2 2025, and $0.04 during Q1 2025.